Mainz Biomed N.V (MYNZ) said Tuesday it has partnered with Thermo Fisher Scientific (TMO) to develop a colorectal cancer screening test.
Financial details of the partnership were not disclosed.
Mainz said the partnership will combine its experience in mRNA-based colorectal cancer detection with Thermo Fisher's technology resources to develop a non-invasive test for detecting early-stage colorectal cancer and precancerous growths.
Shares of Mainz Biomed rose nearly 7% in recent Tuesday trading, while Thermo Fisher's rose 0.3%.
Price: 0.23, Change: +0.01, Percent Change: +6.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments